Thales Introduces S3NS in Partnership With Google Cloud and Unveils Its Offering in a First Step Towards the French Trusted Cloud Label
Thales announced today the creation of S3NS, a French company designed to offer public and private organizations in France the power of Google Cloud, fully compliant with France's “Trusted Cloud” label, in partnership with Google Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005160/en/
(Graphic: Thales)
The new company, majority owned and controlled by Thales, is under French law and follows the October 2021 partnership announcement between Thales and Google Cloud to jointly develop a locally-compliant Trusted Cloud offering. Thales and Google Cloud are committed to helping companies and public institutions to innovate and accelerate their digital transformation in ways that afford autonomy, compliant sovereignty, and the greatest possible benefits for their customers and users.
Meeting the French “Trusted Cloud”
S3NS will offer from the second half of 2024 its “trusted cloud” offering that will ultimately combine full performance, services and applications of Google Cloud technology while allowing protection against extraterritorial foreign laws and in compliance with the requirements of the “Trusted Cloud” label of France’s Information Systems Security Agency (ANSSI) in the frame of the French State strategy. S3NS will directly operate three data centers to ensure data and workload localisation in France. Both data center availability and engineering assistance will be available this year already and the recruitment of engineers who will operate the “Trusted Cloud” will begin.
A first milestone with an offering already available
S3NS' first offering is "Local control with S3NS", which will offer Google Cloud customers in France continued high public cloud performance, with added capabilities to localize clients’ data in France or in Europe, as needed or preferred. Customers will be able to restrict data access for administrative service and technical support solely to European Union locations. Cryptographic control of data access can be achieved with external encryption key management from S3NS. This first offering brings compliance with additional automation to simplify operations, along with additional auditability and transparency to increase customer confidence in cloud operations.
Committing partners already
To best support customers in this transition to the “Trusted Cloud”, S3NS is finalizing specific partnership agreements with various players in France's growing digital ecosystem. Partners will be able to support S3NS customers in their cloud and digital sovereignty strategy, as they migrate and operate their workloads and applications securely, with the help of S3NS’ and other managed services.
“The S3NS offering is the best of both worlds: the agility and wide range of services of a cloud hyperscaler combined with the security and data protection of a cybersecurity leader. This step marks the beginning of a technological and industrial adventure which will engage all the French economic players attached to a trusted solution. As a leader in critical information systems, Thales is once again demonstrating its ability to be a driving force in disruptive technologies.” Marc Darmon, Executive Vice President, Secure Communications and Information Systems at Thales.
“The creation of S3NS, progress on the definition of our Trusted Cloud offering and the availability of our 'Local controls with S3NS' is the result of many months of collaboration between Thales and the Google Cloud teams. This is a first step and a first milestone this year, before our future solution in compliance with the French 'Trusted Cloud' criteria, which we are working on in parallel. Our objective is to be the first to make such an offering available for certification and based on hyperscale cloud technology. 'Local Controls with S3NS' enables our customers to start their journey to the trusted cloud now.” Cyprien Falque, Managing director of S3NS.
“We are very proud to support our partner Thales and its subsidiary S3NS and its first offering in the French market. This collaboration between our teams reflects on the one hand an understanding of the expectations related to digital sovereignty, and on the other hand a real technological trajectory. We confirm the commitments made together in 2021 and will continue to support digital transformation with offers that combine security and sovereignty, without compromising on performance.” Thomas Kurian, CEO at Google Cloud.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021 the Group generated sales of €16.2 billion.
PLEASE VISIT
https://www.linkedin.com/company/s3nscloud/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220630005160/en/
Contact information
Press
Thales, Media Relations
Security
Marion Bonnet
marion.bonnet@thalesgroup.com
+33(0)660384892
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
